CHICAGO, IL -- February 26, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics and the market leader in molecular spectroscopy, today introduced the first in a series of easy-to-use Raman spectroscopy instruments at PITTCON® 2007, Booth 843.  The bench-top RamanStation™ 400 Raman spectrometer combines research-grade performance with push-button ease-of-use. The RamanStation’s dispersive echelle-spectrograph technology allows reliable performance, without the need for moving parts, while enabling detection of the full spectral range at a high resolution in a single acquisition.

Raman is a non-destructive technique based on the detection of scattered light to identify and analyze molecular species.  It is a complementary analytical tool to Fourier Transform Infrared (FT-IR) and Fourier Transform Near-Infrared (FT-NIR) spectroscopy and is used in pharmaceutical, chemical, forensics and academic industries.

“We are committed to providing customers with access to complete analytical solutions, such as this easy-to-use, bench-top Raman instrumentation,” said Simon Wells, Ph.D., Molecular Spectroscopy business unit manager, PerkinElmer Life and Analytical Sciences.  Until now, Raman spectroscopy was limited to a narrow sector of highly skilled researchers trained in complex Raman analysis.  The new RamanStation technology breaks down the barriers and now makes Raman accessible to more than specially trained researchers. “With the push of a button, an operator can obtain high-quality information regarding the identification, composition and molecular structure of samples,” said Wells.

Wells noted that other Raman instruments utilize motorized parts in the optical pathway.  This leads to slow data acquisition and instrument reliability issues. “The RamanStation’s advanced design provides considerably faster data collection and improved data reproducibility, and makes the need for time-consuming alignment obsolete,” he added.

PerkinElmer secured the advanced RamanStation technology through the recent, strategic acquisition of Avalon Instruments.  This technology enables PerkinElmer to more fully support scientists utilizing molecular spectroscopy for sample identification, quantitative analysis and mapping applications in academic and industrial research and forensic science laboratories. 

For more information about the RamanStation 400 Raman Spectrometer, visit www.perkinelmer.com/ramanstation400.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.